Applied Medical Resources Corporation v. Medtronic, Inc., 8:23-cv-00268

Background

Applied Medical Resources and Medtronic compete in the market for advanced bipolar devices (ABDs), used in surgical procedures.
Applied claims Medtronic uses anti-competitive contract practices (bundled discounts, exclusive dealing) to maintain and expand its monopoly in the ABD market.
Hospitals purchase ABDs via locally negotiated agreements (LNAs) or group purchasing organization (GPO) tier commitments; Medtronic offers substantial discounts tied to purchasing commitments.
Applied alleges Medtronic's practices lock hospitals into long-term purchasing, prevent trials of competing products, and foreclose competition.
Medtronic filed a motion for summary judgment, asserting there are no triable issues of fact and Applied has no actionable federal or state antitrust claims.
The court considers federal and state antitrust claims, and whether laches bars injunctive or declaratory relief.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Are Medtronic’s bundled discounts exclusionary under antitrust law?	Bundles fail the Discount Attribution Test (DAT), can exclude equally efficient competitors without need to show substantial foreclosure or market power over each product in bundle.	Bundling not actionable unless DAT shows substantial foreclosure (≥40% of the market) and Medtronic has market power over all bundled products.	Bundling claims survive; no requirement for substantial foreclosure or market power over all products, just monopoly over portfolio breadth and DAT failure.
Do Medtronic’s LNAs and GPO Tier Commitments constitute de facto exclusive dealing?	Agreements, paired with generator/financing arrangements and trial restrictions, practically lock hospitals into exclusivity, not easily terminable.	Contracts are terminable on short notice; insufficient market foreclosure for antitrust violation.	Triable fact issue; evidence supports finding of de facto exclusivity not terminable on short notice.
Has a substantial share of the ABD market been foreclosed by Medtronic’s practices?	Exclusive dealing and bundling practices foreclose at least 24% of the ABD market, enough for liability.	Only smaller market share tied to DAT-failing bundles; asserts this is insufficient for substantial foreclosure.	Sufficient evidence for jury to find substantial foreclosure (≥24%) of ABD market.
Has Applied suffered antitrust injury?	Market would be more competitive and prices lower absent Medtronic’s conduct; restricted growth is actionable injury.	No antitrust injury since competitors, including Applied, remain in market and Applied admits being equally efficient.	Antitrust injury shown; not necessary for plaintiff to be driven from market; restricted growth and lost opportunities suffice.

Key Cases Cited

Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (summary judgment standard)
Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment burden on movant)
Matsushita Elec. Indus. Co., Ltd. v. Zenith Radio Corp., 475 U.S. 574 (summary judgment when no genuine issue of fact)
Cascade Health Sols. v. PeaceHealth, 515 F.3d 883 (bundled discount exclusionary conduct and DAT)
Allied Orthopedic Appliances Inc. v. Tyco Health Care Grp. LP, 592 F.3d 991 (exclusive dealing, market foreclosure)
Omega Env't, Inc. v. Gilbarco, Inc., 127 F.3d 1157 (rule of reason in exclusive dealing)
Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477 (antitrust injury requirement)
Twin City Sportservice, Inc. v. Charles O. Finley & Co., 676 F.2d 1291 (market foreclosure thresholds for antitrust liability)
Masimo Corp. v. Tyco Health Care Grp., L.P., [citation="350 F. App'x 95"] (market share discount agreements as de facto exclusive dealing)